Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve
- 4 September 2017
- journal article
- assisted reproduction-technologies
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 34 (12) , 1645-1651
Abstract
The aim of this study is to determine whether a clinical advantage is gained with use of LH in combination with FSH or as a component of human menopausal gonadotropin (hMG) to achieve optimal ovarian stimulation.Keywords
Funding Information
- None
This publication has 22 references indexed in Scilit:
- Biomarkers of ovarian response: current and future applicationsFertility and Sterility, 2013
- Outcome from consecutive ICSI cycles in patients treated with recombinant human LH and those supplemented with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocolGynecological Endocrinology, 2013
- GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debateReproductive BioMedicine Online, 2013
- LH and hCG Action on the Same Receptor Results in Quantitatively and Qualitatively Different Intracellular SignallingPLOS ONE, 2012
- Ovarian antral folliculogenesis during the human menstrual cycle: a reviewHuman Reproduction Update, 2011
- Luteinizing hormone supplementation in ART2011
- Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trialFertility and Sterility, 2010
- Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysisReproductive Biology and Endocrinology, 2010
- Management of poor ovarian responders in IVFReproductive BioMedicine Online, 2005
- Gonadotrophin Control of Follicular FunctionHormone Research, 1995